Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis

BMC Cancer

Table 1 Characteristics of the included studies

Study	Year	Country	Ethnicity	Design	NOS score	Sample	PE	NE	Gender (M/F)	Age (years)	Method	Stage	ADC	SCC	Others	Treatment	Follw-up(months)
Hasegawa et al.	2001	Japan	Asian	ROS	7	53	–	–	27/26	64	ELISA	I-IV	33	19	1	surgery	41(6–74)
Huang et al.	2014	China	Asian	ROS	8	194	99	95	138/56	–	FFPE	I-IV	107	76	11	surgery	60(5–72)
Kumar et al.	2011	India	Asian	ROS	8	42	–	–	–	55.5	ELISA	I-IV	–	–	–	CT	27.6(14–72)
Kumar et al.	2010	India	Asian	ROS	7	100	–	–	92/8	56	ELISA	III-IV	23	77	0	surgery+CT + RT	27(24–30)
Takanami et al.	1994	Japan	Asian	ROS	7	88	39	49	50/38	61	ELISA	I-IV	88	0	0	surgery	–
Takanami et al.	1997	Japan	Asian	ROS	7	120	66	54	–	–	ELISA	I-IV	120	0	0	surgery	84(60–144)
Xie et al.	2015	China	Asian	ROS	8	85	48	37	61/24	60	ELISA	I-IV	47	28	10	surgery+CT + RT	36(4–74)
Zhao et al.	2010	China	Asian	ROS	8	65	–	–	–	59	ELISA	III	19	42	4	CT + RT	–

ROS Review observational study, FFPE Formalin-Fixed and Parrffin-Embedded, ELISA Enzyme-linked immuno sorbent assay, SCC squamous cell carcinoma, ADC Adenocarcinoma, RT Radiation therapy, CT Chemotherapy, PE Postive expression, NE Negative expression

ISSN: 1471-2407